EU Could Soon Have Three XBB.1.5 COVID-19 Vaccines For Winter Season
Executive Summary
The head of the European Medicines Agency says a group of international regulators got together to ensure “global alignment” on the approach to be taken on COVID-19 vaccination.
You may also be interested in...
Novavax Gets Competitive Shot As Third ’23-’24 COVID-19 Vaccine Provider In US
After long lagging behind Pfizer/BioNTech and Moderna, authorization of its XBB.1.5 variant-based vaccine may give Novavax a boost as an mRNA alternative could be more appealing to some. But unlike its competitors it does not have a pediatric indication.
Coronavirus Notebook: UK Approves Comirnaty XBB.1.5, CEPI & Oxford Uni Strike ‘Disease X’ Vaccine Deal
The Swiss medicines regulator is reviewing an application for Novavax’s vaccine against the XBB.1.5 variant, while ACM Biolabs has announced positive results from a Phase I trial of its COVID-19 booster vaccine, ACM-001.
EU Critical Medicines List To Be Ready ‘Within Days’
Members of the European Parliament were told that once the list was out, work would begin on identifying the products most vulnerable to supply chain problems.